Text Size
101 studies found for:    "Acromegaly"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Recruiting Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Condition: Acromegaly
Interventions: Drug: Pasireotide (SOM230);   Drug: octreotide LAR 30mg;   Drug: lanreotide ATG 120mg
22 Recruiting Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study
Condition: Acromegaly
Intervention:
23 Unknown † Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism.
Conditions: Acromegaly;   Obstructive Sleep Apnea;   Insulin Resistance
Interventions: Device: Continuous positive air pressure device (CPAP);   Other: External nasal dilator adhesive
24 Recruiting Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target
Condition: Acromegaly
Intervention: Drug: Sandostatin® LAR
25 Completed
Has Results 		Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Condition: Acromegaly
Interventions: Drug: Somatuline Autogel (lanreotide acetate);   Behavioral: Home administration
26 Completed Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
Condition: Acromegaly
Intervention: Drug: Lanreotide (Autogel formulation)
27 Unknown † Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant
Conditions: Acromegaly;   Heart Failure;   Hypertrophy, Left Ventricular
Intervention: Drug: pegvisomant
28 Unknown † A Study Examining the Peri- and Post-operative Dynamics of the Growth Hormone (GH) - IGF-1 Axis in Subjects With Acromegaly During the First Year After Surgical Resection
Condition: Acromegaly
Intervention: Other: OGTT
29 Recruiting Efficacy and Safety of Pasireotide LAR in Japanese Patients With Acromegaly or Pituitary Gigantism
Condition: Acromegaly, Pituitary Gigantism
Intervention: Drug: SOM230LAR
30 Completed Physiopathology of Sodium Retention in Acromegaly
Condition: Acromegaly
Intervention: Drug: furosemide
31 Not yet recruiting Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly
Condition: Acromegaly
Intervention: Device: Proton magnetic resonance (MR) spectroscopy
32 Completed Prediction of Tumor Shrinkage in Acromegaly
Condition: Acromegaly
Intervention: Drug: Octreotide-LAR
33 Completed Open Label Study of Octreotide Implant in Patients With Acromegaly
Condition: Acromegaly
Intervention: Drug: octreotide acetate
34 Completed Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
Condition: Acromegaly
Interventions: Drug: Octreotide Implant;   Drug: Sandostatin LAR Depot
35 Completed A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
Condition: Acromegaly
Interventions: Drug: Pegvisomant;   Drug: Sandostatin LAR
36 Completed Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
Condition: Acromegaly
Intervention: Drug: Lanreotide-Autogel 120 mg
37 Completed Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
Condition: Acromegaly
Intervention: Drug: lanreotide (Autogel formulation), duration of treatment 46-48 weeks
38 Recruiting Prospective Study on Changes in Acromegaly
Condition: Acromegaly
Intervention:
39 Active, not recruiting Effects of Sandostatin LAR® in Acromegaly
Condition: Acromegaly
Intervention: Drug: Sandostatin LAR
40 Completed Non Interventional Post Marketing Programme in Acromegaly
Condition: Acromegaly
Intervention:
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years